Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
November 01, 2024 15:05 ET
|
Teva Pharmaceutical Industries Ltd
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental...
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
November 01, 2024 15:00 ET
|
Teva Pharmaceutical Industries Ltd
Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscienceData show TEV-'749 drug delivery technology...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
October 22, 2024 07:00 ET
|
Teva Pharmaceutical Industries Ltd
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
October 08, 2024 07:00 ET
|
Teva Pharmaceutical Industries Ltd
Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia, showed...
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
October 03, 2024 08:30 ET
|
Teva Pharmaceutical Industries Ltd; mAbxience
The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration supports Teva's Pivot to Growth strategy and adds...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024 04:15 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
Alvotech Investigated For Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm
May 03, 2023 11:18 ET
|
Block & Leviton LLP
BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Alvotech (NASDAQ: ALVO) for potential securities law violations. Investors who have lost money in their Alvotech...
Alvotech Investigated For Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm
April 14, 2023 11:22 ET
|
Block & Leviton LLP
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Alvotech (NASDAQ: ALVO) for potential securities law violations. Investors who have lost money in their Alvotech...
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm – TEVA
November 10, 2020 15:10 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA)...